PETACH TIKVA, Israel, May 5, 2016 /PRNewswire/ --
Emerald Medical Applications Corp. (OTCQB: MRLA) ("Emerald" or the "Company"), the Israeli-based company engaged in the development and sale of DermaCompare™, its proprietary artificial intelligence technology and application for the early diagnosis of melanoma and other skin cancers, today announced that Dr. Perry Robins has joined the Company's Medical Advisory Board.
Dr. Robins is Professor Emeritus of Dermatology and was Chief of the Mohs Micrographic Surgery Unit at New York University Medical Center for over forty years. He has performed more than 47,000 Mohs surgical procedures, and trained doctors from around the world. He is also the Founder and President of The Skin Cancer Foundation, an international organization dedicated to skin cancer awareness, research, and public and medical education.
In addition to his work as a surgeon and at his foundation, Dr. Robins continues to be extremely active in other aspects of his field, including:
- Founder-President of the International Society for Dermatologic Surgery;
- Founder and former President of the American College of Mohs Micrographic Surgery;
- Former President of the American Society of Dermatologic Surgery;
- Honorary Fellow at the American Academy of Dermatology for outstanding contributions in dermatology;
- Authored five books and published over sixty articles in leading medical journals and is the founder of the Journal of Dermatologic Surgery and Oncology and the Journal of Drugs in Dermatology.
Commenting on the appointment, Lior Wayn, CEO of Emerald, said, "This is such a significant appointment for us. Dr. Robins is known around the world for his contributions to the field of dermatology, in particular the treatment of skin cancer where his dedication to patients and commitment to education have benefited millions of patients. His experience, insight and expertise will be invaluable as we work to commercialize our DermaCompare technology."
Dr. Robins went on to say, "I am very excited to join Emerald. I have dedicated a large portion of my long career in dermatology to the treatment of skin cancers, but I have never seen anything like DermaCompare. I believe their ability to combine the power of artificial intelligence with the utility of a mobile app will revolutionize the way we detect and diagnose melanoma, and I look forward to working with the company on this endeavor."
About Emerald Medical Applications Corp
Emerald Medical Applications is an Israeli-based medical technology company that utilizes proprietary military image processing technology and state of the art data analytics to improve the analysis of medical images. Emerald's flagship solution, DermaCompare™, is an FDA Class #1 approved, HIPPA-compliant, skin cancer (melanoma) screening platform that enables physicians to identify and monitor changes in their patients' skin health, specifically the early detection of cancerous moles and skin anomalies.
The DermaCompare™ patient application is available in Mac or Android based platforms and works using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography ("TBP") images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patient's previous Total Body Photography images, which will dramatically enhance a physician's ability to detect Melanoma earlier, more accurately and more efficiently than other means of diagnosis.
For more information, visit: http://www.dermacompare.com/
Notice Regarding Forward-Looking Statements
This press release may contain forward-looking statements, about Emerald's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Emerald or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Emerald with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Emerald's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Emerald's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Emerald's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Emerald's filings with the SEC. In addition, Emerald operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Emerald does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Reference is made to the disclosure under "risk factors" included in our Registration Statement on Form S-1 which was declared effective by the U.S. Securities and Exchange Commission on January 20, 2016.
Lior Wayn, CEO
SOURCE Emerald Medical Applications Corp.